Pfizer, BioNTech start consolidated preliminaries of COVID-19 immunization candidate in Japan Kumar Jeetendra | October 20, 2020 Pfizer Inc and BioNTech SE announced on Tuesday the start in Japan of combined Phase I and Phase II clinical trials of the mRNA vaccine candidate against the coronavirus. Earlier, they had agreed to supply Japan with 120 million doses of their experimental coronavirus vaccine in the first half of 2021. Pfizer, which is developing …
